Repetitive Infusion of Levosimendan in Patients with Chronic Heart Failure: A Meta-Analysis

Gui-yan Yi
Jun-xia Li
Jian Zhang
Li-li Niu
Cai-yun Zhang

Corresponding Author: Jun-xia Li, e-mail: junxiali1@126.com

Source of support: Self financing

Background: Repetitive or intermittent levosimendan infusion is gradually becoming more commonly considered for patients with advanced chronic heart failure. However, previous randomized controlled studies (RCTs) reported conflicting results on the effects of levosimendan when administered repetitively. The aim of this meta-analysis was to generate up-to-date evidence to assess the effect of levosimendan in this group of patients.

Material/Methods: A literature review identified 8 qualified studies. A meta-analysis was performed to assess mortality and left ventricular ejection fraction (LVEF).

Results: Use of levosimendan contributed to significantly reduced mortality at the end of mid-term follow-up. The mortality rates in levosimendan and control group were 23 of 226 (10.2%) and 53 of 198 (26.8%), respectively (RR: 0.40, 95%CI: 0.26–0.63, P<0.0001). The trend of significantly decreased mortality was observed in levosimendan vs. placebo subgroup (RR: 0.28, 95%CI: 0.15–0.54, P=0.0001, I²=0%) but not in levosimendan vs. dobutamine, PGE1, or furosemide subgroup (p=0.19, p=0.64 and p=0.25, respectively). Levosimendan also contributed to significantly improved LVEF improvement at the end of follow-up (mean difference: 3.69%, 95CI: 0.92–6.45%, p=0.009).

Conclusions: Intermittent or repetitive levosimendan infusion might be a promising strategy to reduce mortality and improve LVEF in patients with advanced chronic, but not necessarily acutely decompensated, heart failure to maintain disease stability.

MeSH Keywords: Heart Failure • Meta-Analysis • Treatment Outcome

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/893736
Background

Beta-blockers have been demonstrated to be reliable medication for patients with heart failure (HF) and are currently used as first-line treatment in combination with angiotensin-converting enzyme (ACE) inhibitors [1,2]. Although the administration of combined beta-blockers and ACE inhibitors may bring some benefits for this group of patients, chronic heart failure might still be progressive, and a large proportion of the patients eventually develop decompensation. Therefore, these patients may need inotropic agents to improve hemodynamics. Intravenous infusion of inotropes is widely applied as a practice to get more definitive measures or as palliative treatment for decompensation of chronic heart failure [3]. A single administration is insufficient to generate long-lasting results and affect outcome [4]. However, intermittent or continuous treatment of chronic heart failure with intravenous inotropes might increase the risk of proarrhythmic effects and subsequent mortality [5].

Levosimendan is an inotropic agent stabilizing the open conformation of troponin C and the troponin C-calcium-tropomyosin complex and enhancing calcium sensitivity of cardiac myofilaments [6]. However, unlike other positive inotropic agents, the effect of levosimendan is not dependent on cellular calcium intake or intracellular ionized calcium concentration [7]. Therefore, this agent does not impair ventricular relaxation and does not cause intracellular calcium overload and associated arrhythmias. In addition, levosimendan can also lead to vasodilatation through opening adenosine triphosphate-dependent potassium channels [8]. Therefore, based on the inotropic and vasodilatory functions, levosimendan can result in increased cardiac output, without excessive myocardial oxygen demand [9,10]. Due to this benefit, this agent is considered for repetitive or intermittent use in patients with advanced chronic heart failure [11]. However, previous RCTs reported conflicting results in the effects of levosimendan when administered repetitively. The aim of this meta-analysis was to generate up-to-date evidence to assess the effect of levosimendan in this group of patients.

Material and Methods

Search strategy

Relevant studies were searched in PubMed, MEDLINE, Cochrane Library, and ClinicalTrials.com from Jan 1995 to May 2014 by 2 authors independently (YGY and LJX). The whole search was based on the following terms and strategy: (“levosimendan” OR “simdax”) AND (“chronic” OR “congestive”) AND (“heart failure” OR “HF”) AND (“repetitive” OR “Intermittent” OR “continuous”) AND (“randomized controlled trial” OR “RCT” OR “clinical trial” OR “trial”). No language restriction was set during searching. To ensure all qualified studies were included, backward snowballing method was performed by manual screening of introduction and reference list of included studies, relevant meta-analysis, and reviews.

Study selection and selection criteria

Studies meeting the following include criteria at the same time were included in this meta-analysis: (1) randomized controlled trial; (2) recruited patients with advanced chronic heart failure; (3) had at least 2 arms comparing intermittent use of levosimendan and control group (other agents/best available treatment/placebo); (4) efficacy outcomes, such as mortality, could be extracted from original studies; (5) duration of follow-up lasted at least 1 month. Studies meeting any of the following criteria were excluded: (1) oral administration of levosimendan; (2) non-adult studies; (3) incomplete or lack of required data. Two authors performed screening and selection independently. Divergences were resolved by group discussion with a third author by referring to original studies.

Data extraction, study quality, and bias assessment

The following information about basic characteristics of a study were extracted: last name of the first author, year of publication, regime of intervention and control group, number of patients in each group, dose and duration of agent administered, lapse, and duration of follow-up. Outcome data extracted for efficacy analysis mainly included mortality at the end of follow-up and left ventricular ejection fraction (LVEF) improvement. Quality of the included RCTs was assessed by methodological quality item of RCT according to the Cochrane Handbook for Systematic Reviews of Interventions. Internal validity and publication bias were assessed by Cochrane Collection methods. Publication bias was assessed by visually inspecting funnel plots.

Data synthesis and analysis

All data synthesis and analysis in this study were performed using RevMan 5.2 software (Cochrane Collaboration). Discontinuous outcome (mortality) and continuous outcome (LVEF) from individual studies were extracted and pooled to make estimate of risk ratios (RR) and corresponding 95% confidence intervals (CIs). Between-studies heterogeneity was measured with the chi-square-based Q test and I². P<0.1 or I²>50% was considered as significant heterogeneity. A primary analysis was conducted with a fixed-effects model. If I²≤50% and p≥0.1, a fixed-effects model with Mantel-Haenszel method was used to make estimates, otherwise a random-effects model was used. The significance of pooled estimates was assessed with the Z test and p<0.05 was considered as statistically significant difference. © Med Sci Monit, 2015; 21: 895-901
Results

Characteristics of studies included

Through a search of databases, a total of 8 studies were finally included in this meta-analysis. The whole search process is briefly described in Figure 1. Among the 8 studies included, 5 compared levosimendan vs. placebo [12–16]; 1 compared levosimendan vs. dobutamine [17]; 1 compared levosimendan vs. furosemide [18], and 1 compared levosimendan vs. prostaglandin E1 (PGE1) [19]. The 8 studies involved 453 patients in total, with 245 in levosimendan groups and 208 in control groups. The basic characteristics of the trials are summarized in Table 1. Seven studies reported mid-term mortality, but the study by Parissis et al. [15] did not. All patients in these trials were recruited in cardiological settings, defined as heart failure caused by heart diseases except cardiac surgery. Four studies applied a continuous infusion of levosimendan without the bolus dose [12,16–18]. Dose of continuous infusion ranged from 0.1 to 0.4 μg/kg/min. Follow-up ranged from 114 days to 16 months. The intervals of administration were weekly, every 2 weeks, every 3 weeks, monthly, and every 2 months. Therefore, the clinical heterogeneity was largely related to dose, control treatment, and follow-up duration. Quality assessment showed that 5 studies had a moderate risk of bias [13,14,16,18,19] and 3 had a low risk of bias [12,15,17].

Mid-term mortality

The mid-term mortality reported by 7 trials was pooled in Figure 2. Due to no between-studies heterogeneity observed ($I^2=0\%$), a fixed-effects model was used. Generally, use of levosimendan contributed to significantly reduced mortality at the end of follow-up. The mortality rates in levosimendan and control groups are compared in Table 1. The key characteristics of trials included.

Table 1. The key characteristics of trials included.

| Study            | No Pts | Levo bolus (μg/kg) | Levo infusion (μg/(kg·min)) | Duration Levo (h) | Lapse | Control agent | Follow up (d) |
|------------------|--------|-------------------|-------------------------------|-------------------|-------|---------------|---------------|
| Altenberger 2014 | 63     | 0                 | 0.2                          | 6                 | Bi-weekly | Placebo        | 26 wks        |
| Bonios 2012      | 21     | 0                 | 0.3                          | 6                 | Weekly | Dobu           | 6 m           |
| Berger 2007      | 39     | 12                | 0.1                          | 24                | Monthly | PGE1           | 12 m          |
| Levin 2009       | 40     | 0                 | 0.1                          | 24                | Bi-monthly | Placebo        | 12 m          |
| Malfatto 2012    | 22     | 0                 | 0.1–0.4                      | 24                | Monthly | Furosemide     | 16 m          |
| Mavrogeni 2007   | 25     | 6                 | 0.1–0.2                      | 24                | Monthly | Placebo        | 6 m           |
| Kleber 2009      | 18     | 12                | 0.2                          | 23                | Bi-weekly | Placebo        | 12 wks        |
| Parissis 2006    | 17     | 6                 | 0.1–0.4                      | 24                | 3 weekly | Placebo        | 114 d         |

Levo – levosimendan; Dobu – dobutamine; No. Pts – number of patients; PGE1 – prostaglandin E1; wks – weeks; m – month; d – day.

Figure 1. The searching and screening process.
control groups were 23 of 226 (10.2%) and 53 of 198 (26.8%), respectively (RR: 0.40, 95%CI: 0.26–0.63, P<0.0001) (Figure 2). Due to heterogeneous agents used in the control group, subgroup analysis was also performed. The trend of significantly decreased mortality was observed in levosimendan vs. placebo subgroups (RR: 0.28, 95%CI: 0.15–0.54, P=0.0001, I²=0%) (Figure 2). However, in levosimendan vs. dobutamine, PGE1, or furosemide subgroups, no significant difference was observed (p=0.19, p=0.64 and p=0.25, respectively) (Figure 2). In comparison to dobutamine, furosemide, or PGE1, there was only 1 study that included in each subgroup. Funnel plot analysis showed that the mid-term mortality outcomes of the 7 trials had symmetric distribution, suggesting there was no publication bias (Figure 3).

**Left ventricular ejection fraction (LVEF) improvement**

Five studies have reported LVEF improvement data in both intervention and control groups during the whole follow-up period.

---

**Table 1. Study characteristics and meta-analysis results.**

| Subgroup | Events | Total | Risk ratio M-H, fixed, 95% CI | Heterogeneity |
|----------|--------|-------|-----------------------------|---------------|
| 1.1.1 Levo vs. Placebo | 10 | 63 | 0.23 [0.03, 1.96] | Chi²=0.23, df=3 (P=0.97); I²=0% |
| Altenberg 2014 | 23 | 57 | 3.78 [1.12, 12.01] | Test for overall effect: Z=3.80 (P=0.0001) |
| Kleber 2009 | 0 | 16 | 0.18 [0.01, 3.91] | |
| Levin 2009 | 6 | 40 | 0.32 [0.14, 0.71] | |
| Mavrogeni 2007 | 2 | 25 | 0.25 [0.06, 1.06] | |
| Subtotal (95% CI) | 144 | 320 | 0.28 [0.15, 0.54] | |
| Total events | 9 | 32 | | |

**Figure 2.** Meta-analysis of mortality rate at the end of follow-up.

**Figure 3.** Funnel plot analysis of the mid-term mortality outcomes.
Discussion

Two recent meta-analyses also assessed the use of levosimendan in chronic advanced heart failure patients [11,20]. However, these 2 studies simply pooled all studies with different control arms into 1 group. This method is prone to generate significant heterogeneity and also failed to evaluate the difference in comparisons with different control arms. In the current study, stratified analysis was performed to make overall estimation of all studies and to compare therapeutic effect difference with different control arm at the same time. Our findings provided updated evidence about the effect of repetitive administration of levosimendan in chronic advanced heart failure patients and found the use of levosimendan is associated with a significant reduced mortality risk in mid-term follow-up and improved LVEF in a cardiologic setting. However, the effect is generally more evident when compared with placebo, rather than dobutamine, PGE1, or furosemide.

For patients with end-stage chronic heart failure, prognosis is always poor. Long-term mechanical circulatory support or heart transplantation could significantly improve prognosis. However, limited availability of assist devices and donor heart, lack of professional expertise, and high cost make these choices impossible for a large proportion of the patients [21]. Although inotrope therapy could provide improvement in hemodynamic function, long-term and intermittent use of inotropic agents is not recommended for patients in current treatment guidelines [3]. At present there is no large randomized, placebo-controlled trial that has assessed the efficacy of intermittent intravenous inotropes for decompensated end-stage chronic heart failure.

The SURVIVE study compared the efficacy and safety of levosimendan vs. dobutamine for patients with acute heart failure

| Study or subgroup | Levo | SD | Total | Mean | Control | SD | Total | Weight | Risk ratio | Risk ratio |
|-------------------|------|----|-------|------|---------|----|-------|--------|------------|------------|
| **Subtotal (95% CI)** | 1.2.1 Levo vs. Placebo | | | | | | | | | |
| Mavrioni 2007 | 28 | 7 | 25 | 21 | 4 | 25 | 25.1% | 7.00 [3.84, 10.16] | | |
| Parisios 2006 | 26 | 5 | 17 | 22 | 4 | 18 | 22.4% | 4.00 [0.35, 7.65] | | |
| Heterogeneity: Tau²=1.46; Chi²=1.48, df=1 (P=0.22); I²=33% | | | | | | | | | |
| Test for overall effect: Z=3.78 (P=0.0002) | | | | | | | | | |

| Subtotal (95% CI) | 1.2.2 Levo vs. Dobutamine | | | | | | | | | |
| Bonios 2012 | 30.2 | 8 | 21 | 25 | 4.4 | 21 | 21.4% | 5.20 [1.30, 9.10] | | |
| Subtotal (95% CI) | 1.2.4 Levo vs. Furosemide | | | | | | | | | |
| Malaffi 2007 | 28.7 | 5.4 | 22 | 28 | 6.3 | 11 | 19.4% | 0.70 [–3.65, 5.05] | | |
| Subtotal (95% CI) | Total (95% CI) | | | | | | | | | |
| Heterogeneity: Tau²=5.32; Chi²=8.93, df=4 (P=0.06); I²=55% | | | | | | | | | | |
| Test for overall effect: Z=2.61 (P=0.009) | | | | | | | | | | |
| Test for subgroup differences: Chi²=6.74, df=3 (P=0.08); I²=55.5% | | | | | | | | | | |

Figure 4. Meta-analysis of LVEF comparisons at the end of follow-up.

Due to significant heterogeneity observed (I²=55%), a random-effects model was used. Pooled results showed that use of levosimendan contributed to significantly improved LVEF at the end of follow-up (mean difference: 3.69%, 95%CI: 0.92–6.45%, p=0.009, I²=55%) (Figure 4). Similar to mid-term mortality, subgroup analysis showed that LVEF improvement was quite significant in levosimendan vs. placebo subgroups (mean difference: 5.65%, 95%CI: 2.72–8.57%, p=0.0002, I²=33%) (Figure 4). However, the effect was generally more evident when compared with placebo, rather than dobutamine, PGE1, or furosemide. In comparison to dobutamine, furosemide, or PGE1, there was only 1 study included in each subgroup.

For patients with end-stage chronic heart failure, prognosis is always poor. Long-term mechanical circulatory support or heart transplantation could significantly improve prognosis. However, limited availability of assist devices and donor heart, lack of professional expertise, and high cost make these choices impossible for a large proportion of the patients [21]. Although inotrope therapy could provide improvement in hemodynamic function, long-term and intermittent use of inotropic agents is not recommended for patients in current treatment guidelines [3]. At present there is no large randomized, placebo-controlled trial that has assessed the efficacy of intermittent intravenous inotropes for decompensated end-stage chronic heart failure.
in a cardiological setting. Although this study found that short-term infusion of levosimendan had no obvious benefits over dobutamine in all-cause mortality at 180 days or any other secondary clinical outcomes [22], the effect of continuous use is still not well defined and the unique pharmacokinetic features of levosimendan make it an ideal agent for intermittent weekly infusions. The positive inotropic effects of levosimendan is mainly related to its effect on to troponin C and calcium, stabilizing conformational change of tropomyosin molecule, and prolonging tropomyosin contraction through enhancing actin-myosin overlap, without increasing the concentration of intracellular calcium [23]. The half-life of this agent is about 1 h and its active metabolite OR-1896, which had similar pharmacologic properties as the original agent, has a half-life of 80–90 h [23]. Thus, with a single intravenous administration, the hemodynamic effects of hemodynamic effects can last 1 to 2 weeks [24]. Therefore, intermittent use of levosimendan might bring even longer-term benefits for the patients. According to a previous study, levosimendan is helpful to improve cardiac function or even generate favorable reverse cardiac remodeling through activation of pro-inflammatory cytokines and the deleterious neurohormonal systems [25]. Actually, Parissis et al. observed that levosimendan infusion contributed to significant decrease in plasma N-terminal-pro BNP and interleukin 6, through which to active neurohormonal and immune responses [15].

According to the recommendation of the European guidelines for diagnosis and treatment of acute and chronic heart failure [26], inotropic agents could be considered for acute or chronic heart failure patients with hypoperfusion and/or hypotension to increase blood pressure and cardiac output, and to improve peripheral perfusion. However, due to the possible negative arrhythmias and myocardial ischemic effects, electrocardiogram should be monitored continuously. Levosimendan is classified as a class IIa recommendation. It is a unique agent, different from other inotropic agents since its positive inotropic effects do not need excessive myocardial oxygen consumption [23]. Therefore, it did not increase workload of the heart. β-adrenergic agonist or PDE inhibitors can all cause complications such as myocardial injury, ischemia, and arrhythmia. Although some studies reported that levosimendan presented PDE-III inhibitor effects at higher concentrations (0.3 μM), it does not cause these complications in the clinically recommended therapeutic range (0.03–0.3 μM or 10–100 ng/mL) and mainly acts as a Ca2+ sensitizer at the recommended concentration range [27]. Actually, in a recent expert panel consensus, 30 experts from 15 countries agreed that intermittent or repetitive levosimendan could be considered for patients with advanced chronic, but not necessarily acutely decompensated, heart failure to maintain disease stability [12]. Therefore, levosimendan might be a promising agent for this group of patients.

This study also has several limitations. Firstly, the number of trails and the number of patients in each trial is relatively small. Secondly, the experimental arm of included studies had heterogeneity in the dose and the interval of levosimendan administration, while the control arm had heterogeneity in agents used. Therefore, this study made subgroup analysis to separate different control agents. However, due to the limited number of original studies, the number of patients in each subgroup is small, which weakened the statistical power of the findings. Thirdly, the follow-up of included trials was relatively short. The long-term effects of serial levosimendan infusions are still not quite clear. Therefore, in the future, large RCTs with long-term follow-up are required to assess levosimendan as a part of standard therapy for chronic heart failure. Currently, there are 3 on-going studies assessing the use of levosimendan in advanced chronic heart failure patients (NCT01536132, NCT00988806, and NCT01290146). In the near future, we can expect more solid evidence.

Conclusions

Intermittent or repetitive levosimendan infusion might be a promising strategy to reduce mortality and improve LVEF for patients with advanced chronic, but not necessarily acutely decompensated, heart failure to maintain disease stability.

References:

1. Packer M, Coats AJ, Fowler MB et al: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med, 2001; 344: 1651–58
2. Rouleau JL, Roeker EB, Tendera M et al: Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: The carvedilol prospective randomized cumulative survival (copernicus) study. J Am Coll Cardiol, 2004; 43: 1423–29
3. Hunt SA, Abraham WT, Chin MH et al: 2009 focused update incorporated into the acc/aha 2005 guidelines for the diagnosis and management of heart failure in adults: A report of the american college of cardiology foundation/american heart association task force on practice guidelines: Developed in collaboration with the international society for heart and lung transplantation. Circulation, 2009; 119: e391–479
4. Felker GM, O’Connor CM: Inotropic therapy for heart failure: An evidence-based approach. Am Heart J, 2001;142: 393–401
5. Rapezzi C, Bracchetti G, Branzi A, Magnani B: The case against outpatient parenteral inotropic therapy for advanced heart failure. J Heart Lung Transplant, 2000; 19: 558–63
6. Gheorghiade M, Teerlik JF, Mebazaa A: Pharmacology of new agents for acute heart failure syndromes. Am J Cardiol, 2005; 96: 68G–73G
7. Haikala H, Kaheinen P, Levijoki J, Linden IB: The role of camp- and cgm-dependent protein kinases in the cardiac actions of the new calcium sensitizing, levosimendan. Cardiovasc Res, 1997; 34: 536–46
8. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N: The novel calcium sensitizer levosimendan activates the atp-sensitive k+ channel in rat ventricular cells. J Pharmacol Exp Ther, 1997; 283: 375–83
9. Ukkonen H, Saraste M, Akkila J et al: Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther, 2000; 68: 522–31
10. Tasal A, Demir M, Kanadasi M et al: Comparison of single-dose and repeated levosimendan infusion in patients with acute exacerbation of advanced heart failure. Med Sci Monit, 2014; 20: 276–82

11. Nieminen MS, Altenberger J, Ben-Gal T et al: Repetitive use of levosimendan for treatment of chronic advanced heart failure: Clinical evidence, practical considerations, and perspectives: An expert panel consensus. Int J Cardiol, 2014; 174: 360–67

12. Altenberger J, Parissis JT, Costard-Jaeckle A et al: Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (levorep) study: A multicentre randomized trial. Eur J Heart Fail, 2014; 16: 896–906

13. Mavrogeni S, Giannouzis G, Papadopoulou E et al: A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure. J Card Fail, 2007; 13: 556–59

14. Kleber FX, Bollmann T, Borst MM et al: Repetitive dosing of intravenous levosimendan improves pulmonary hemodynamics in patients with pulmonary hypertension: Results of a pilot study. J Clin Pharmacol, 2009; 49: 109–15

15. Parissis JT, Adamopoulos S, Farmakis D et al: Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart, 2006; 92: 1768–72

16. Levin RP, Tanus R, Degrange M: Abstract 3815: The intermittent infusion of levosimendan reduces mortality and re-admissions in patients with advanced heart failure. Circulation, 2009; 120: S865

17. Bonios MJ, Terrovitis JV, Drakos SG et al: Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure. Int J Cardiol, 2012; 159: 225–29

18. Malfatto G, Della Rosa F, Villani A et al: Intermittent levosimendan infusions in advanced heart failure: Favourable effects on left ventricular function, neurohormonal balance, and one-year survival. J Cardiovasc Pharmacol, 2012; 60: 450–55

19. Berger R, Moertl D, Huelsmann M et al: Levosimendan and proaglandin E1 for titration of beta-blockade in patients with refractory, advanced chronic heart failure. Eur J Heart Fail, 2007; 9: 202–8

20. Silvetti S, Greco T, Di Prima A, et al: Intermittent levosimendan improves mid-term survival in chronic heart failure patients: Meta-analysis of randomised trials. Clin Res Cardiol, 2014; 103: 505–13

21. Thackray S, Easthaugh J, Freemantle N, Cleland JG: The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure—a meta-regression analysis. Eur J Heart Fail, 2002; 4: 515–29

22. Mavrogeni S, Giannouzis G, Papadopoulou E et al: Levo-rep in advanced heart failure: A multicentre randomized trial. Int J Cardiol, 2014; 174: 360–67

23. Antila S, Sundberg S, Lehtonen LA: Clinical pharmacology of levosimendan. Clin Pharmacokinet, 2007; 46: 535–52

24. Figgitt DP, Gillies PS, Goa KL: Levosimendan. Drugs, 2001; 61: 613–27; discussion 628–29

25. Erdel N, Papp Z, Pollesello P et al: The levosimendan metabolite or-1896 elicits vasodilation by activating the k(atp) and bk(ca) channels in rat isolated arterioles. Br J Pharmacol, 2006; 148: 696–702

26. McMurray JJ, Adamopoulos S, Anker SD et al: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. Eur J Heart Fail, 2012; 14: 803–89

27. Papp Z, Edes I, Fruhwald S et al: Levosimendan: Molecular mechanisms and clinical implications: Consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol, 2012; 159: 82–87